These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 8863366)

  • 1. Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever.
    Engervall P; Günther G; Ljungman P; Lönnqvist B; Hast R; Stiernstedt G; Kalin M; Ringertz S; Bjökholm M
    Scand J Infect Dis; 1996; 28(3):297-303. PubMed ID: 8863366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
    Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
    Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
    Hung KC; Chiu HH; Tseng YC; Wang JH; Lin HC; Tsai FJ; Peng CT
    J Microbiol Immunol Infect; 2003 Dec; 36(4):254-9. PubMed ID: 14723254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimethoprim-sulfamethoxazole plus amikacin as first-line therapy and imipenem/cilastatin as second empirical therapy in febrile neutropenic patients with hematological disorders.
    Engervall PA; Stiernstedt GT; Günther GC; Björkholm MJ
    J Chemother; 1992 Apr; 4(2):99-106. PubMed ID: 1629753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients.
    Glauser MP; Brennscheidt U; Cornely O; Grigg A; Figuera A; Keyserling C; Trostmann U; Welling L; Tack K
    Clin Microbiol Infect; 2002 Jan; 8(1):14-25. PubMed ID: 11906496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients.
    Behre G; Link H; Maschmeyer G; Meyer P; Paaz U; Wilhelm M; Hiddemann W
    Ann Hematol; 1998 Feb; 76(2):73-80. PubMed ID: 9540761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
    Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of fever in neutropenic patients with acute leukemia: current role of ceftazidime plus amikacin as empiric therapy.
    Fanci R; Paci C; Martinez RL; Fabbri A; Pecile P; Leoni F; Longo G
    J Chemother; 2000 Jun; 12(3):232-9. PubMed ID: 10877519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
    Hess U; Böhme C; Rey K; Senn HJ
    Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer.
    Ariffin H; Arasu A; Mahfuzah M; Ariffin WA; Chan LL; Lin HP
    J Paediatr Child Health; 2001 Feb; 37(1):38-43. PubMed ID: 11168867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefepime as empirical monotherapy in febrile patients with hematological malignancies and neutropenia: a randomized, single-center phase II trial.
    Engervall P; Kalin M; Dornbusch K; Björkholm M
    J Chemother; 1999 Aug; 11(4):278-86. PubMed ID: 10465130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study.
    Erman M; Akova M; Akan H; Korten V; Ferhanoğlu B; Köksal I; Cetinkaya Y; Uzun O; Unal S;
    Scand J Infect Dis; 2001; 33(11):827-31. PubMed ID: 11760163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever.
    Giamarellou H; Bassaris HP; Petrikkos G; Busch W; Voulgarelis M; Antoniadou A; Grouzi E; Zoumbos N
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3264-71. PubMed ID: 11083625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia.
    Serefhanoglu K; Ersoy Y; Serefhanoglu S; Aydogdu I; Kuku I; Kaya E
    Ann Acad Med Singap; 2006 Jan; 35(1):11-6. PubMed ID: 16470268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.
    Marie JP; Marjanovic Z; Vekhoff A; Bouvet A; Chast F; Levy V; Baudard M; Legrand O; Rio B; Delmer A; Zittoun R
    Support Care Cancer; 1999 Mar; 7(2):89-94. PubMed ID: 10089089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients.
    Malik IA; Abbas Z; Karim M
    Lancet; 1992 May; 339(8801):1092-6. PubMed ID: 1349112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.
    Jimeno A; Arcediano A; Bazares S; Amador ML; González-Cortijo L; Ciruelos E; Robles L; Castellano D; Paz-Ares L; Lumbreras C; Hornedo J; Cortés-Funes H
    Clin Transl Oncol; 2006 Dec; 8(12):889-95. PubMed ID: 17169762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
    Agaoglu L; Devecioglu O; Anak S; Karakas Z; Yalman N; Biner B; Eryilmaz E; Goksan B; Unuvar A; Agirbasli H; Can M; Bilgen H; Gedikoglu G
    J Chemother; 2001 Jun; 13(3):281-7. PubMed ID: 11450887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors.
    Kebudi R; Görgün O; Ayan I; Gürler N; Akici F; Töreci K
    Med Pediatr Oncol; 2001 Apr; 36(4):434-41. PubMed ID: 11260566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.